These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29041931)

  • 1. Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.
    Yang Z; Yang X; Xu S; Jin P; Li X; Wei X; Liu D; Huang K; Long S; Wang Y; Sun C; Chen G; Hu J; Meng L; Ma D; Gao Q
    Mol Cancer; 2017 Oct; 16(1):163. PubMed ID: 29041931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Yang Z; Jin P; Xu S; Zhang T; Yang X; Li X; Wei X; Sun C; Chen G; Ma D; Gao Q
    Cancer Lett; 2018 Feb; 415():20-29. PubMed ID: 29199004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
    Blanco-Gómez A; Hontecillas-Prieto L; Corchado-Cobos R; García-Sancha N; Salvador N; Castellanos-Martín A; Sáez-Freire MDM; Mendiburu-Eliçabe M; Alonso-López D; De Las Rivas J; Lorente M; García-Casas A; Del Carmen S; Abad-Hernández MDM; Cruz-Hernández JJ; Rodríguez-Sánchez CA; Claros-Ampuero J; García-Cenador B; García-Criado J; Orimo A; Gridley T; Pérez-Losada J; Castillo-Lluva S
    Cancer Res; 2020 Dec; 80(23):5216-5230. PubMed ID: 33023950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
    Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal responses among common carcinomas correlated with clinicopathologic features.
    Chen JL; Espinosa I; Lin AY; Liao OY; van de Rijn M; West RB
    Clin Cancer Res; 2013 Sep; 19(18):5127-35. PubMed ID: 23804424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.
    Hamalian S; Güth R; Runa F; Sanchez F; Vickers E; Agajanian M; Molnar J; Nguyen T; Gamez J; Humphries JD; Nayak A; Humphries MJ; Tchou J; Zervantonakis IK; Kelber JA
    Oncogene; 2021 Aug; 40(33):5224-5235. PubMed ID: 34239043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. lncRNA AC005224.4/miR-140-3p/SNAI2 regulating axis facilitates the invasion and metastasis of ovarian cancer through epithelial-mesenchymal transition.
    Xiong T; Wang Y; Zhang Y; Yuan J; Zhu C; Jiang W
    Chin Med J (Engl); 2023 May; 136(9):1098-1110. PubMed ID: 36939239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.
    Yang Z; Xu S; Jin P; Yang X; Li X; Wan D; Zhang T; Long S; Wei X; Chen G; Meng L; Liu D; Fang Y; Chen P; Ma D; Gao Q
    Oncotarget; 2016 Jun; 7(25):37649-37663. PubMed ID: 27081703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.
    Li X; Yang Z; Xu S; Wang Z; Jin P; Yang X; Zhang Z; Wang Y; Wei X; Fang T; Gao Q
    Dis Markers; 2019; 2019():7275289. PubMed ID: 31827640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer.
    Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q
    Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
    Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
    Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer.
    Benhadjeba S; Edjekouane L; Sauvé K; Carmona E; Tremblay A
    Mol Oncol; 2018 Oct; 12(10):1689-1705. PubMed ID: 30051594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts.
    Schauer IG; Zhang J; Xing Z; Guo X; Mercado-Uribe I; Sood AK; Huang P; Liu J
    Neoplasia; 2013 Apr; 15(4):409-20. PubMed ID: 23555186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
    Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
    J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.
    Zhang D; Jiang Z; Hu J; Sun X; Zheng Y; Shen Y
    Front Immunol; 2023; 14():1117585. PubMed ID: 37251370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.
    Sundararajan V; Tan M; Tan TZ; Ye J; Thiery JP; Huang RY
    Sci Rep; 2019 Jun; 9(1):8295. PubMed ID: 31165775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.
    Dong P; Xiong Y; Watari H; Hanley SJ; Konno Y; Ihira K; Yamada T; Kudo M; Yue J; Sakuragi N
    J Exp Clin Cancer Res; 2016 Sep; 35(1):132. PubMed ID: 27596137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer.
    Feng S; Xu Y; Dai Z; Yin H; Zhang K; Shen Y
    Front Immunol; 2022; 13():951582. PubMed ID: 35874760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
    Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
    Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIEF2 over-expression promotes tumor growth and metastasis through reprogramming of glucose metabolism in ovarian cancer.
    Zhao S; Zhang X; Shi Y; Cheng L; Song T; Wu B; Li J; Yang H
    J Exp Clin Cancer Res; 2020 Dec; 39(1):286. PubMed ID: 33317572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.